2024
Why selective screening for asymptomatic carotid stenosis is currently appropriate: a special report
Paraskevas K, Dardik A, Schermerhorn M, Liapis C, Mansilha A, Lal B, Gray W, Brown M, Myrcha P, Lavie C, Zeebregts C, Secemsky E, Saba L, Blecha M, Gurevich V, Silvestrini M, Blinc A, Svetlikov A, Fernandes e Fernandes J, Schneider P, Gloviczki P, White C, AbuRahma A. Why selective screening for asymptomatic carotid stenosis is currently appropriate: a special report. Expert Review Of Cardiovascular Therapy 2024, 22: 159-165. PMID: 38480465, DOI: 10.1080/14779072.2024.2330660.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsScreening programMass screening programPopulation-wide screening programsRisk factor modificationHigh riskHigh risk of strokeMyocardial infarctionInitiation of preventive measuresRisk of strokeIntensive medical therapyAsymptomatic carotid artery stenosisFactor modificationCost-effectiveLifestyle measuresPrevent future strokeAsymptomatic carotid stenosisTargeted screeningCarotid artery stenosisFuture strokeScreening of populationsCarotid revascularization proceduresProphylactic carotid interventionMedical therapyPreventive measuresCV events
2021
Vessel Wall Enhancement on Black-Blood MRI Predicts Acute and Future Stroke in Cerebral Amyloid Angiopathy
McNally JS, Sakata A, Alexander MD, Dewitt LD, Sonnen JA, Menacho ST, Stoddard GJ, Kim S, de Havenon AH. Vessel Wall Enhancement on Black-Blood MRI Predicts Acute and Future Stroke in Cerebral Amyloid Angiopathy. American Journal Of Neuroradiology 2021, 42: 1038-1045. PMID: 33737266, PMCID: PMC8191668, DOI: 10.3174/ajnr.a7047.Peer-Reviewed Original ResearchConceptsCerebral amyloid angiopathyFuture ischemic strokeVessel wall enhancementIschemic strokeAmyloid angiopathyWall enhancementFuture strokeC-statisticVessel wall MRNew-onset neurologic symptomsInitial ischemic strokeStroke-free survivalAcute ischemic strokeIschemic stroke incidenceCAA patientsFinal regression modelNeurologic symptomsStroke incidenceCerebral amyloidCox regressionRetrospective studyRisk factorsMultivariable PoissonNegative participantsAngiopathy
2017
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction
Kernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit R, Fayad P, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurology 2017, 74: 1319-1327. PMID: 28975241, PMCID: PMC5710663, DOI: 10.1001/jamaneurol.2017.2136.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic attackMyocardial infarctionIschemic strokeHigh riskPioglitazone groupInsulin resistanceLower riskCox proportional hazards regression modelProportional hazards regression modelsMedian riskEfficacy of pioglitazoneInsulin Resistance InterventionQualifying ischemic strokePlacebo-controlled trialHazards regression modelsLow baseline riskType 2 diabetesGreater absolute benefitDay of entryFuture strokeHydrochloride therapyPlacebo groupHazard ratioSecondary prevention
2014
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2014, 45: 2160-2236. PMID: 24788967, DOI: 10.1161/str.0000000000000024.Peer-Reviewed Original ResearchConceptsTransient ischemic attackEvidence-based recommendationsIschemic attackCerebral venous sinus thrombosisTimely evidence-based recommendationsAntiphospholipid antibody syndromeVenous sinus thrombosisPrevention of strokeAortic arch atherosclerosisSickle cell diseaseImplementation of guidelinesAntibody syndromeFuture strokeRecurrent strokeAnticoagulation therapyAntiplatelet therapyAntithrombotic therapySinus thrombosisIschemic strokeNoncardioembolic strokeSecondary preventionArterial dissectionHypercoagulable statePatent foramenIntracranial hemorrhage
2009
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics
Bushnell C, Zimmer L, Schwamm L, Goldstein L, Clapp-Channing N, Harding T, Drew L, Zhao X, Peterson E. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics. American Heart Journal 2009, 157: 428-435.e2. PMID: 19249411, DOI: 10.1016/j.ahj.2008.11.002.Peer-Reviewed Original ResearchConceptsIschemic stroke Longitudinal (AVAIL) registryTransient ischemic attackIschemic attackRecurrent strokePrevention medicationsLongitudinal registryAdherence evaluationSecondary preventive therapyBaseline patient characteristicsModified Rankin scoreSecondary prevention measuresMedication-taking behaviorSystem-level barriersLevel of adherenceFuture strokeCardiovascular eventsRankin scoreVascular eventsAcute hospitalizationHospital dischargePatient characteristicsPreventive therapySecondary outcomesMedication usePrimary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply